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Polish epidemiological and statistical data, and a systematic review (proportion of 
patients treated with antipsychotic drugs who withdrew because of adverse events). 
Current and predicted market shares were assessed on the basis of present sales level 
data. RESULTS: In the ﬁ rst scenario, NHF expenditures on atypical antipsychotic 
drugs will increase by: 13 mln PLN in 2010, 20 mln PLN in 2011 and 26 mln PLN 
in 2012. In the second scenario of no sertindole reimbursement NHF expenditures on 
atypical antipsychotic drugs will increase by: 11 mln PLN in 2010, 18 mln PLN in 
2011 and 23 mln PLN in 2012. From patient’s perspective, expenditures will increase 
in 2010–2012 by 0.9 mln PLN 1.3 mln PLN and 1.7 mln respectively in scenario with 
sertindole reimbursement, while in a second scenario costs will increase in 2010–2012 
by 1.1 mln PLN, 1.6 mln PLN and 2.0 mln PLN respectively. The 2009 weighted 
average exchange rate of Polish National Bank was c1 = PLN 4.3273. CONCLU-
SIONS: Reimbursement of sertindole would result in a minor increase in Polish NHF 
expenditures. Simultaneously, it would enlarge the scope of accessible therapies for 
patients intolerant to at least one other antipsychotic agent.
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OBJECTIVES: Generic medicines are generally considerably less expensive than 
branded products and their endorsement can lead to substantial savings in costs. The 
main objective of the study was to calculate potential cost savings that can be gener-
ated by generic substitution of antidepressants within the private health care sector of 
South Africa. METHODS: Data on computerised medicine claims of patients receiving 
one or more antidepressants during three consecutive years (i.e. 2004, 2005 and 2006) 
were elicited from a South African pharmaceutical beneﬁ t management company. a 
non-experimental, quantitative, retrospective drug utilization review was conducted 
and data were analyzed using the Statistical Analysis System® programme. Potential 
cost savings deﬁ ned as the collective amount that could be saved annually by substitut-
ing the average price of innovator active substances for that of generic equivalent(s) 
were computed for criteria-eligible substances in the study population. All costs are 
expressed in $U.S. RESULTS: A total of 292,071 items (N = 5,982,869) on 273,673 
prescriptions (N = 5,213,765) at a total cost of $8,652,289.48 (N = $207,316,483.10) 
were included in the study. Generic products constituted 58.7% (n = 292,071) of all 
antidepressants claimed, at a total cost of 28.2% (N = $207,316,483.10) of all 
incurred costs. With total substitution of the average price of all criteria-eligible 
innovators, a potential saving of 9.3% (N = $8,652,289.48) of the actual antidepres-
sant cost over the study period, was calculated. CONCLUSIONS: In developing 
countries with limited health care budgets, such as South Africa, generic substances 
can be cost-saving treatment alternatives. Health care professionals, third-party 
payers, and patients all have fundamental roles to play in order to encourage greater 
use of generics. Medicine expenditure can thereby be reduced and access to scarce 
resources increased, in order to meet the pressing health care needs within South 
Africa.
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OBJECTIVES: To estimate the impact of amisulpride continued reimbursement in 
schizophrenia treatment on payer’s budget in Poland. METHODS: The analysis was 
performed in 5-year time horizon from the payer (National Health Fund, NHF) 
perspective and payer + patient perspective. Only costs of medicines were included. 
On the base of IMS Health Poland sale data for years 2005–2010 linear regression 
was conducted to predict consumption and prevalence of antipsychotics in Poland. 
Cost data of medicines were obtained from Ministry of Health and medicine portals 
in case of lack of reimbursement. One-way sensitivity analysis were performed for the 
key input parameters. RESULTS: From the payer perspective, cost of amisulpride is 
approximately c7.13 million in 2010 and c9.15 million in 2014 and it represents from 
4.62% in 2010 to 4.28% in 2014 of the total cost of schizophrenia treatment esti-
mated at approximately c154.22 million in 2010 and c213.87 million in 2014. From 
the payer + patient perspective, cost of amisulpride is approximately c7.26 million in 
2010 and c9.32 million in 2014 and it represents from 4.01% in 2010 to 3.85% of 
the total cost of schizophrenia treatment estimated at approximately c181.11 million 
in 2010 and c241.81 million in 2014. Increase of NHF and patients expenses is related 
to an increase of antipsychotics sales over a span of the next ﬁ ve years caused by 
expanding awareness of schizophrenia and the importance of treatment. CONCLU-
SIONS: Our ﬁ ndings suggest that the cost of treatment with amisulpride are at a 
reasonable level and represent a small proportion of the total costs of schizophrenia 
treatment both from the payer perspective and common payer + patient perspective. 
The declining trend in the share of amisulpride cost in total cost of schizophrenia is 
noticeable. Amisulpride is an alternative therapeutic option of schizophrenia treatment 
in Poland and its reimbursement from public funds is justiﬁ ed.
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OBJECTIVES: To compare the health care costs 6 months prior to and 6 months after 
initiation of pregabalin in generalized anxiety disorder (GAD) patients in Sweden. 
METHODS: This was a retrospective longitudinal database study of GAD patients from 
the South-West region of Sweden (1.5 million inhabitants). Individual patient data on 
health care visits (outpatient, inpatient, primary care), costs, mortality and diagnoses 
were included from year 2000. Data from the Swedish Prescribed Drug Register were 
included from July 1, 2005 until December 31, 2007. Patients with a GAD (ICD-10 
F41.1) diagnosis and who initiated pregabalin treatment in 2006 were included. Health 
care utilization was measured six months before and six months after pregabalin initia-
tion. Patients with 2 or more prescriptions of benzodiazepines six months prior to 
pregabalin initiation were categorized as benzodiazepine patients. Non-parametric sta-
tistical tests (Mann-Whitney) were used for the cost and resource use comparisons. 
RESULTS: A total of 149 patients met the inclusion criteria, of whom 99 used benzo-
diazepines prior to pregabalin treatment. The number of in-patient (P < 0.05) and 
primary care (P < 0.05) visits signiﬁ cantly decreased in the 6-month period following 
pregabalin initiation. There was also a statistically signiﬁ cant reduction (p = 0.0004) in 
overall health care costs from SEK 71,000 (c7,408) to SEK 45,000 (c4,695). Among 
the benzodiazepine users (n = 99), the number of in-patient visits (p = 0.0213), days in 
hospital (p = 0.0026) and primary care visits (p = 0.0121) were all statistically signiﬁ -
cantly reduced following pregabalin initiation. The reduction in total cost (from SEK 
79,000 to SEK 43,000; c8,243 to c4,486) among the users of benzodiazepines was also 
statistically signiﬁ cant (p = 0.0001). The decrease in total cost, in all patients as well as 
benzodiazepine treated, was to a large extent explained by the decrease in in-patient 
costs. CONCLUSIONS: Initiating treatment with pregabalin in GAD patients signiﬁ -
cantly reduced health care utilization and costs during the following 6 months.
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OBJECTIVES: There is accumulating evidence of sub-therapeutic second-generation 
antipsychotic (SGA) dosing for patients diagnosed with bipolar disorder, leading to 
suboptimal control of disease and higher overall treatment costs. The objectives of 
this study were to identify Medicaid bipolar patients receiving clinically effective doses 
of SGAs and compare their medical costs. METHODS: Patients with bipolar disorder 
taking an oral SGA (aripiprazole, olanzapine, quetiapine, risperidone or ziprasidone) 
were identiﬁ ed in Medicaid claims databases (2005–2008) from 8 US states. Patients 
were followed for 18 months (6-month pre-index period during which patients did 
not receive an SGA, followed by a 12-month post-index utilization period to determine 
total costs). For patients on recommended dosing, costs were compared using a gen-
eralized linear model with a gamma distribution and log-link function. Baseline 
covariates (age, gender, race, pre-index costs, Charlson co-morbidity score, and spe-
ciﬁ c psychiatric co-morbidities) were adjusted for. Ziprasidone-treated patients com-
prised the reference group. RESULTS: A total of 2446 patients met inclusion criteria, 
with 45% (N = 1102) taking clinically effective doses by day 61 of their follow-up 
period. Patients on quetiapine had the lowest percentage of effective dosing at 26% 
(N = 280/1072). Other results were aripiprazole 77% (N = 336/448), olanzapine 52% 
(N = 118/226), risperidone 50% (N = 238/474), and ziprasidone 58% (N = 130/226). 
Regression analyses indicated that mental health-related prescription costs (P < 0.01) 
and all-prescription costs (P < 0.01) were statistically signiﬁ cantly lower for the ris-
peridone group compared to the ziprasidone group. There were no signiﬁ cant differ-
ences between the groups for total mental health-related costs or total all-cause costs 
(includes prescription and medical services). CONCLUSIONS: Less than half of the 
patients in this sample were prescribed clinically recommended doses 2 months after 
their initial start. Among patients using recommended doses, while those on risperi-
done had lower prescription costs, there were no signiﬁ cant differences for total costs 
compared to patients taking ziprasidone.
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OBJECTIVES: This study investigates the health care costs of adverse events (AE) 
associated with treatment of bipolar disorder with two atypical antipsychotics (AA): 
aripiprazole (ARI) and Olanzapine (OLA). METHODS: It was performed a cost 
analysis through a markov model considering the following health states: no existence 
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of adverse events (NAE); extrapyramidal symptoms (EPS); weight gain (WG); and 
sexual dysfunction (SD). The transition probabilities amongst health states were 
estimated from two different meta-analysis of clinical trials and from a retrospective 
Spanish study. The health care costs associated to each health state were obtained 
from a published Spanish study. It was used the minimum acquisition cost per mg. of 
the mean daily dose, for each AA, which is regarded as a relevant efﬁ ciency criterion 
in Hospital Pharmacy Departments. The time horizon applied in the analysis was 12 
months. a probabilistic sensitivity analysis was performed for all the variables involved 
in the analysis via Monte Carlo simulations. All costs were inﬂ ated to 2009 costs using 
Spanish Health System pay and prices index. RESULTS: In comparison with OLA, the 
treatment with ARI generates annual average cost savings per patient of c−688.70 ± 
21.69 (CI 95% −614.52; −729.18). In the most unfavourable scenario for ARI, that in 
which we assumed that ARI may have a similar rate of sexual dysfunction than that of 
quetiapine (i.e. the lowest rate amongst AA) the costs savings per patient would be 
c–270,94 ± 17,11 (CI 95% −237,20; −303,48). CONCLUSIONS: The results of this 
analysis show that patients treated with aripiprazole demonstrate lower adverse events 
costs in comparison to olanzapine. This difference may generate signiﬁ cant cost 
savings to the Spanish health system in the treatment of patients affected by bipolar 
disorders. The robustness of the results was tested via a probabilistic sensitivity 
analysis.
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OBJECTIVES: Real-world treatment patterns and health care resource utilization for 
patients with GAD in the United States are not fully deﬁ ned. METHODS: Data from 
the 2003–2007 Thomson Reuters MarketScan® Commercial Claims and Encounters 
and Medicare Supplemental and Coordination of Beneﬁ ts databases were utilised for 
analysis. For the current analysis, participants with a diagnosis of GAD (ICD-9 CM 
300.02) between January 1, 2004 and December 31, 2006 were included. The sample 
was divided into the following ﬁ ve subgroups: patients receiving non-pharmacological 
treatment, ﬁ rst-line therapy only, ﬁ rst-line + augmentation within 90 days of index 
prescription, ﬁ rst-line + switch within 90 days of index prescription and second-line 
therapy only. Additionally, GAD patients were compared with healthy controls 
without GAD or other mental health conditions. RESULTS: In total, 23,553 GAD 
patients (mean age range: 41.6–48.1 years; 56.1–68.6% female across the ﬁ ve groups) 
were included (non-pharmacological, n = 7055; ﬁ rst-line only, n = 6538; ﬁ rst-line + 
augmentation, n = 903; ﬁ rst-line + switch, n = 1953; second-line only, n = 7104). 
Paroxetine was the most commonly used ﬁ rst-line treatment at index (ﬁ rst-line cohorts: 
48%, 42%, 41%, respectively). In the second-line only cohort, a benzodiazepine 
(37%) or second-line SSRI/SNRI (27%) were the most commonly used agents at index. 
Benzodiazepines were the most commonly prescribed agents for augmentation of, or 
switching from, ﬁ rst-line treatments (augmentation 52%, switch 44%). Overall, GAD 
patients had higher health care utilization and signiﬁ cantly higher total health care 
costs versus healthy controls (mean per patient: $8058 vs. $2938, P < 0.0001). On 
average, GAD patients incurred an additional $425/month in direct health care costs 
in the 1-year post-index period versus healthy controls. CONCLUSIONS: The real-
world management of GAD is both complex and costly. Paroxetine was the most-
widely used ﬁ rst-line treatment for GAD. Benzodiazepines were the most widely used 
agents for augmentation of, or switching from, ﬁ rst-line treatments, and for second-
line therapy. Total health care costs were 2.7 times higher for GAD patients compared 
with healthy controls.
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OBJECTIVES: There is a paucity of published evidence estimating the economic and 
humanistic burden of illness in GAD. We report results of a retrospective database 
analysis examining the burden of GAD in Europe. METHODS: Data were derived 
from the European (France, Germany, UK, Italy, Spain) National Health and Wellness 
Survey database for 2008. The database captures information from adults (≥18 years) 
and is representative of the adult population in each country. Respondents reporting 
a diagnosis of GAD were propensity-score matched 1:1 to non-GAD controls on 
country, age, gender and employment status. Data were extracted on GAD medication 
use, resource utilization (emergency room visits, hospitalizations and health care 
provider visits) and work productivity (using the Work Productivity and Activity 
Impairment questionnaire) to calculate direct and indirect costs. Health-related quality 
of life (HRQoL) was derived using SF-12 mental and physical summary scores. Utili-
ties were derived from SF-6D preference scores and used to calculate cost per quality-
adjusted life-year (QALY). RESULTS: Of 53,524 respondents, 3,669 were assigned 
to the GAD group. GAD respondents accrued considerably higher direct (medication 
and health care resources) plus indirect (work productivity loss) costs (per person/
year) versus controls across pooled European countries (c5,308.80 vs. c2,441.10; P 
< 0.0001) and for each country (France c6,083.70 vs. c2,896.30; Germany c12,797.00 
vs. c4,876.10; UK c4,021.70 vs. c2,011.20; Italy c3,514.50 vs. c1,869.60; Spain 
c5,051.70 vs. c1,954.80; P < 0.0001 vs. controls within each country). Direct costs 
were driven by hospitalizations and psychologist/psychiatrist visits. Total costs 
increased with GAD severity from c4,094.00 for respondents with mild GAD to 
c7,753.10 for those with severe GAD. HRQoL was signiﬁ cantly poorer for GAD 
versus non-GAD respondents (P < 0.0001). Costs/QALY increased with GAD severity 
from c6,795 for mild GAD to c15,286 for severe GAD. CONCLUSIONS: The eco-
nomic and humanistic burden of illness of GAD across Europe is considerable and 
increases with the severity of disease.
PMH17
COST OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN 
GERMANY
Braun S1, Zeidler J1, Linder R2, Ahrens S2, Manouguian MS2, Greiner W3
1Leibniz University of Hannover, Hannover, Germany; 2Scientiﬁ c Institute of Techniker 
Krankenkasse for Beneﬁ t and Efﬁ ciency in Health Care, Hamburg, Germany; 3University of 
Bielefeld, Bielefeld, Germany
OBJECTIVES: Data concerning costs of patients with Attention deﬁ cit/hyperactivity 
disorder (ADHD) are scarce in Germany. Aim of this claims data analysis was to 
examine the costs of ADHD from the perspective of the statutory health insurance. 
METHODS: Nation-wide claims data of a major statutory health insurance fund was 
used to evaluate the overall and ADHD-related costs of ADHD-patients in 2008. All 
costs for outpatient care, inpatient care, pharmaceuticals, rehabilitation, occupational 
therapy as well as devices and aids, and sick leave payments were analyzed. To cal-
culate ADHD-related costs the overall health care costs of the identiﬁ ed ADHD-
patients were compared to an age and gender matched control group. RESULTS: 
Based on the used identiﬁ cation algorithm 30,264 ADHD-patients were identiﬁ ed. 
Mean overall costs of c3802 in the year 2008 were incurred from the health insurance 
perspective. c1704 (45%) were incurred by occupational therapy as well as devices 
and aids, and c779 (20%) were due to inpatient care; c751 (20%) resulted from 
outpatient care. Costs for pharmaceuticals were c483 (13%) and for rehabilitation 
were c35 (≤1%). Costs for sick leave payments came to c50 (1%). The matched 
control group contains 404,565 patients. Compared to this control group the incre-
mental mean costs of ADHD-patients were EUR 2,744. EUR 1,214 of these resulted 
from occupational therapy as well as devices and aids, c586 from inpatient care and 
c517 from outpatient care. Mean additional costs for pharmaceuticals in the ADHD-
group were c367. CONCLUSIONS: The major cost driver in ADHD from a health 
insurance perspective in Germany is occupational therapy as well as devices and aids.
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OBJECTIVES: To investigate the burden of depression in the Swiss population. The 
costs for the management of depressive patients will be analyzed for different severity 
classes of disease, based on the Hamilton depression rating scale, over a period of 12 
months following diagnosis. METHODS: A prospective, multicentre, non-interven-
tional study in psychiatrist practices was carried out. Patients who have been diag-
nosed with depression in the last three years were included. Patient’s characteristics 
and resource utilization in the ﬁ rst twelve months after diagnosis were collected. Costs 
analysis, subdivided in direct and indirect costs, was performed for three depression 
classes (mild, moderate, severe), according to the Hamilton depression score (HAMD-
17). Costs were also extrapolated to the national level. RESULTS: A total of 556 
patients were included. Hospitalization and hospitalization days were directly corre-
lated with disease severity (P < 0.001). Medical resource utilization linked to depres-
sion and antidepressant treatments were also correlated to disease status. Severe 
patients reported a signiﬁ cantly higher number of workdays lost and were signiﬁ cantly 
more often in disability insurance. Total direct costs per person, mainly due to hos-
pitalization costs, were CHF 4,823 for mild, CHF 13,251 for moderate, and CHF 
22,138 for severe depressions. Indirect costs, mainly due to workdays lost, resulted in 
CHF 11,892 for mild, CHF 17,267 for moderate, and CHF 22,710 for severe depres-
sions. Extrapolation at national level resulted in a total burden of about CHF 11 
billion. CONCLUSIONS: The burden of depression in Switzerland was estimated to 
be around CHF 11 billion. Costs of depression were directly related to disease severity. 
However, since many depressions remain unreported and since this analysis only 
included individuals between 18 and 65 years of age, it is reasonable to suppose that 
the total burden of depression may be even greater.
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OBJECTIVES: Major depressive disorder (MDD) is a leading cause of disability, 
morbidity, and mortality worldwide. The lifetime prevalence in the US is 17%. Treat-
ment resistant depression (TRD) is generally deﬁ ned as failure to achieve remissions 
